This website is an independent initiative of the historic and founding shareholders of OSE Immunotherapeutics. It is not the company's corporate website. Its purpose is to inform other shareholders and stakeholders about our positions and proposals in the context of the debate on strategy and governance.

Bio Shihong EN

Shihong Nicolau

Shihong Nicolau

For over 20 years, Shihong managed a large IP portfolio at the Office of Innovation and Commercialization (aka TTO) at University of California at San Diego. In this influential role, she devised strategies for the university inventions and intellectual property portfolio, driving commercial development. Her responsibilities encompassed invention evaluation, IP due diligence, patent strategy development, IP/technology agreements, and contract/sponsorship compliance.

Prior to her comprehensive IP role in the university, Shihong had many years of experiences at biotech and pharma industry. During her tenure at Pfizer, ( Agouron acquired by Warner-Lambert then Pfizer) she made significant contributions in the research and development of antiviral and anticancer drugs, supporting clinical trials and FDA regulatory approval. Shihong currently works as IP advisor with NPS consulting firm and TPLG; and she is the principal advisor at LARTA institute.

150 150 OSE Immuno Together
Share